AGHAEGBULAM UGA: Open Payments
NPI 1083925945 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,393 in 111 payments from 14 companies in 2025. Trend: 2023 $30,494 · 2024 $18,669 · 2025 $20,393
Speaker / faculty: $16,260Food & beverage: $2,690Travel & lodging: $1,442
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 28 | $18,593 |
| E.R. Squibb & Sons, L.L.C. | 9 | $241 |
| Lundbeck LLC | 6 | $224 |
| Otsuka America Pharmaceutical, Inc. | 11 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $177 |
| Vanda Pharmaceuticals Inc. | 11 | $173 |
| ABBVIE INC. | 9 | $166 |
| Axsome Therapeutics, Inc. | 6 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $156 |
| Teva Pharmaceuticals USA, Inc. | 5 | $143 |
Products named: SPRAVATO, REXULTI, COBENFY, TRINTELLIX, FANAPT, VRAYLAR, CAPLYTA, Auvelity.
Industry payments across TX — which companies pay providers there.
